GSTDTAP

浏览/检索结果: 共3条,第1-3条 帮助

已选(0)清除 条数/页:   排序方式:
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 期刊论文
Science, 2020
作者:  Qian Zhang;  Paul Bastard;  Zhiyong Liu;  Jérémie Le Pen;  Marcela Moncada-Velez;  Jie Chen;  Masato Ogishi;  Ira K. D. Sabli;  Stephanie Hodeib;  Cecilia Korol;  Jérémie Rosain;  Kaya Bilguvar;  Junqiang Ye;  Alexandre Bolze;  Benedetta Bigio;  Rui Yang;  Andrés Augusto Arias;  Qinhua Zhou;  Yu Zhang;  Fanny Onodi;  Sarantis Korniotis;  Léa Karpf;  Quentin Philippot;  Marwa Chbihi;  Lucie Bonnet-Madin;  Karim Dorgham;  Nikaïa Smith;  William M. Schneider;  Brandon S. Razooky;  Hans-Heinrich Hoffmann;  Eleftherios Michailidis;  Leen Moens;  Ji Eun Han;  Lazaro Lorenzo;  Lucy Bizien;  Philip Meade;  Anna-Lena Neehus;  Aileen Camille Ugurbil;  Aurélien Corneau;  Gaspard Kerner;  Peng Zhang;  Franck Rapaport;  Yoann Seeleuthner;  Jeremy Manry;  Cecile Masson;  Yohann Schmitt;  Agatha Schlüter;  Tom Le Voyer;  Taushif Khan;  Juan Li;  Jacques Fellay;  Lucie Roussel;  Mohammad Shahrooei;  Mohammed F. Alosaimi;  Davood Mansouri;  Haya Al-Saud;  Fahd Al-Mulla;  Feras Almourfi;  Saleh Zaid Al-Muhsen;  Fahad Alsohime;  Saeed Al Turki;  Rana Hasanato;  Diederik van de Beek;  Andrea Biondi;  Laura Rachele Bettini;  Mariella D’Angio’;  Paolo Bonfanti;  Luisa Imberti;  Alessandra Sottini;  Simone Paghera;  Eugenia Quiros-Roldan;  Camillo Rossi;  Andrew J. Oler;  Miranda F. Tompkins;  Camille Alba;  Isabelle Vandernoot;  Jean-Christophe Goffard;  Guillaume Smits;  Isabelle Migeotte;  Filomeen Haerynck;  Pere Soler-Palacin;  Andrea Martin-Nalda;  Roger Colobran;  Pierre-Emmanuel Morange;  Sevgi Keles;  Fatma Çölkesen;  Tayfun Ozcelik;  Kadriye Kart Yasar;  Sevtap Senoglu;  Şemsi Nur Karabela;  Carlos Rodríguez-Gallego;  Giuseppe Novelli;  Sami Hraiech;  Yacine Tandjaoui-Lambiotte;  Xavier Duval;  Cédric Laouénan;  COVID-STORM Clinicians†;  COVID Clinicians†;  Imagine COVID Group†;  French COVID Cohort Study Group†;  CoV-Contact Cohort†;  Amsterdam UMC Covid-19 Biobank†;  COVID Human Genetic Effort†;  NIAID-USUHS/TAGC COVID Immunity Group†;  Andrew L. Snow;  Clifton L. Dalgard;  Joshua D. Milner;  Donald C. Vinh;  Trine H. Mogensen;  Nico Marr;  András N. Spaan;  Bertrand Boisson;  Stéphanie Boisson-Dupuis;  Jacinta Bustamante;  Anne Puel;  Michael J. Ciancanelli;  Isabelle Meyts;  Tom Maniatis;  Vassili Soumelis;  Ali Amara;  Michel Nussenzweig;  Adolfo García-Sastre;  Florian Krammer;  Aurora Pujol;  Darragh Duffy;  Richard P. Lifton;  Shen-Ying Zhang;  Guy Gorochov;  Vivien Béziat;  Emmanuelle Jouanguy;  Vanessa Sancho-Shimizu;  Charles M. Rice;  Laurent Abel;  Luigi D. Notarangelo;  Aurélie Cobat;  Helen C. Su;  Jean-Laurent Casanova
收藏  |  浏览/下载:21/0  |  提交时间:2020/10/26
Autoantibodies against type I IFNs in patients with life-threatening COVID-19 期刊论文
Science, 2020
作者:  Paul Bastard;  Lindsey B. Rosen;  Qian Zhang;  Eleftherios Michailidis;  Hans-Heinrich Hoffmann;  Yu Zhang;  Karim Dorgham;  Quentin Philippot;  Jérémie Rosain;  Vivien Béziat;  Jérémy Manry;  Elana Shaw;  Liis Haljasmägi;  Pärt Peterson;  Lazaro Lorenzo;  Lucy Bizien;  Sophie Trouillet-Assant;  Kerry Dobbs;  Adriana Almeida de Jesus;  Alexandre Belot;  Anne Kallaste;  Emilie Catherinot;  Yacine Tandjaoui-Lambiotte;  Jeremie Le Pen;  Gaspard Kerner;  Benedetta Bigio;  Yoann Seeleuthner;  Rui Yang;  Alexandre Bolze;  András N. Spaan;  Ottavia M. Delmonte;  Michael S. Abers;  Alessandro Aiuti;  Giorgio Casari;  Vito Lampasona;  Lorenzo Piemonti;  Fabio Ciceri;  Kaya Bilguvar;  Richard P. Lifton;  Marc Vasse;  David M. Smadja;  Mélanie Migaud;  Jérome Hadjadj;  Benjamin Terrier;  Darragh Duffy;  Lluis Quintana-Murci;  Diederik van de Beek;  Lucie Roussel;  Donald C. Vinh;  Stuart G. Tangye;  Filomeen Haerynck;  David Dalmau;  Javier Martinez-Picado;  Petter Brodin;  Michel C. Nussenzweig;  Stéphanie Boisson-Dupuis;  Carlos Rodríguez-Gallego;  Guillaume Vogt;  Trine H. Mogensen;  Andrew J. Oler;  Jingwen Gu;  Peter D. Burbelo;  Jeffrey I. Cohen;  Andrea Biondi;  Laura Rachele Bettini;  Mariella D'Angio;  Paolo Bonfanti;  Patrick Rossignol;  Julien Mayaux;  Frédéric Rieux-Laucat;  Eystein S. Husebye;  Francesca Fusco;  Matilde Valeria Ursini;  Luisa Imberti;  Alessandra Sottini;  Simone Paghera;  Eugenia Quiros-Roldan;  Camillo Rossi;  Riccardo Castagnoli;  Daniela Montagna;  Amelia Licari;  Gian Luigi Marseglia;  Xavier Duval;  Jade Ghosn;  HGID Lab§;  NIAID-USUHS Immune Response to COVID Group§;  COVID Clinicians§;  COVID-STORM Clinicians§;  Imagine COVID Group§;  French COVID Cohort Study Group§;  The Milieu Intérieur Consortium§;  CoV-Contact Cohort§;  Amsterdam UMC Covid-19 Biobank§;  COVID Human Genetic Effort§;  John S. Tsang;  Raphaela Goldbach-Mansky;  Kai Kisand;  Michail S. Lionakis;  Anne Puel;  Shen-Ying Zhang;  Steven M. Holland;  Guy Gorochov;  Emmanuelle Jouanguy;  Charles M. Rice;  Aurélie Cobat;  Luigi D. Notarangelo;  Laurent Abel;  Helen C. Su;  Jean-Laurent Casanova
收藏  |  浏览/下载:15/0  |  提交时间:2020/10/26
Multispecific drugs herald a new era of biopharmaceutical innovation 期刊论文
NATURE, 2020, 580 (7803) : 329-338
作者:  Gallego, Laura D.;  Schneider, Maren;  Mittal, Chitvan;  Romanauska, Anete;  Carrillo, Ricardo M. Gudino;  Schubert, Tobias;  Pugh, B. Franklin;  Koehler, Alwin
收藏  |  浏览/下载:31/0  |  提交时间:2020/07/03

The modern biopharmaceutical industry traces its roots to the dawn of the twentieth century, coincident with marketing of aspirin-a signature event in the history of modern drug development. Although the archetypal discovery process did not change markedly in the first seven decades of the industry, the past fifty years have seen two successive waves of transformative innovation in the development of drug molecules: the rise of '  rational drug discovery'  methodology in the 1970s, followed by the invention of recombinant protein-based therapeutic agents in the 1980s. An incipient fourth wave is the advent of multispecific drugs. The successful development of prospectively designed multispecific drugs has the potential to reconfigure our ideas of how target-based therapeutic molecules can work, and what it is possible to achieve with them. Here I review the two major classes of multispecific drugs: those that enrich a therapeutic agent at a particular site of action and those that link a therapeutic target to a biological effector. The latter class-being freed from the constraint of having to directly modulate the target upon binding-may enable access to components of the proteome that currently cannot be targeted by drugs.